1. United States Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Etao International Co., Ltd.

Etao International Co., Ltd.

OOTC:ETAOF
0.00
USD
0.00
(0.00%)
1.34BMarket Cap
Etao International Co., Ltd.
OTC:ETAOF
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
TTM
USD
10.09
10.98
- -
Revenue per Share
-1.99
-169.64
- -
Basic EPS, GAAP
-0.49
1.93
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
27.61
-2.95
0.3
Book Value per Share
-2.95
-3.16
0.3
Tangible Book Value per Share
5
5
5
Basic Weighted Avg Shares
53
58
- -
Sales/Revenue/Turnover
-10.17
-1,269.63
- -
Operating Margin (%)
2
2
- -
Depreciation Expense
-11
-897
- -
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
-19.77
-1,544.4
- -
Profit Margin (%)
-12
-8
2
Working Capital
6
5
2
LT Debt
154
-6
2
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'22
Jun'23
ST Debt
10
- -
LT Borrowings
- -
1
LT Finance Leases
5
- -
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
5
5
Market Capitalization
- -
1,342

Working Capital

USD

•

in mil. unless spec.
Dec'22
Jun'23
Total Current Assets
26
3
Cash, Cash Equivalents & STI
12
1
Accounts Receivable, Net
8
1
Inventories
2
- -
Total Current Liabilities
34
1
Payables & Accruals
21
1
ST Debt
10
- -
Deferred Revenue
1
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-103.88%
Free Cash Flow
- -
- -
-490.74%
Net Income, GAAP
- -
- -
8,404.67%
Sales/Revenue/Turnover
- -
- -
8.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
53
2022
- -
- -
- -
58
58
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.99
2022
- -
- -
- -
-169.6
-169.64
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
ETAO International Co., Ltd. (ETAOF) operates as a digital healthcare company that develops an integrated ecosystem encompassing online telemedicine, artificial intelligence diagnostics, big data evaluation, online insurance, pharmacy services, biotechnology solutions, offline hospitals, and specialty clinics including infertility treatment, orthopedic surgery, plastic surgery, primary care, and digital diabetes management. The company, incorporated in 2020 and headquartered in New York, New York with operations across North America, China, Canada, Latin America, and Australia, maintains a network of 12 hospitals, 30 clinics, and digital platforms serving over 5 million registered users. ETAO International delivers AI-driven precision medicine, OMO (online-merge-offline) healthcare, and cross-border networks powered by technologies such as cloud pharmacy transactions, EMR analysis, online consultations, and AI cancer screening. Recent strategic acquisitions include HiPatho for digital pathology, DiaCarta for precision diagnostics, and 6D Dental for AI dental imaging, contributing to over 12 global healthcare capability enhancements and unaudited 2024 consolidated revenue exceeding $150 million USD with pro forma 2025 projections surpassing $660 million USD. In March 2024, the company executed a 1-for-20 reverse share split, increased authorized shares, and altered its share capital structure. ETAO International targets Nasdaq relisting by Q4 2025 following Q1-Q3 2025 milestones in legal planning, acquisition finalization, regulatory approvals, and operational integration, supported by internal cash reserves, PIPE funding, and strategic equity partners focused on dental, AI medical technology, and U.S. healthcare assets.